Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Accelr8 Technology Corp. (AXK) Announces Results Of Two Studies And Receives Approval To Present A New Blood Study

|Includes: Accelerate Diagnostics, Inc. (AXDX)

Accelr8 Technology today announced the promising results of two studies that it presented at the 112th annual General Meeting of the American Society for Microbiology.

The first study involved the use of Accelr8's BACcel™ rapid automated diagnostic system with positive blood cultures to identify a significant, complex multi-drug resistance expression type know as "ESBL." The study showed that the system was capable of maintaining 100% sensitivity and 94% specificity while decreasing time to result by 1-2 days over the best standard method used today. Identifying ESBL resistance has become an incredibly important endeavor, as ESBL resistance has spread across the globe with hundreds of molecular variants, and has migrated past hospitals into communities. These particular resistance types are challenging to detect and sharply reduce treatment options in the largest family of Gram-negative pathogens.

The second study was used to track the performance of the Company's rapid, fully automated specimen preparation technology. The results of the study showed that the BAC-Xtrax™ gel electrofiltration system has the ability to concentrate live bacteria and substantially clear the sample from complex interference in just 10 minutes or less. The BAC-Xtrax™ was able to concentrate live cells more than 100-fold from the original samples, a result that outperforms the best standard method by more than 10 times. It recovered nearly all of the organisms in the samples, with variation on par with that of the quantitative culturing reference method.

Separately, Accelr8 also received notice of acceptance to present results at ICAAC 2012 for a new study titled "Same-Day Blood Culture with Digital Microscopy." The study examines alternatives for shortening the currently typical overnight delay for cultures before beginning analysis of blood-borne infections.

For further information, please visit www.accelr8.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html